Physician profile
Thamar Adams
NPI 1619631710
$6,971.34
in general payments reported to CMS, 2019-2025
30 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $299 · 2023: $2,167 · 2024: $2,547 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,578 · Education: $94.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,577.93 |
| Education | $94.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,695.60 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,099.60 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $982.30 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $625.55 | 2023-2025 | Dupixent |
| Harmony Biosciences LLC | $454.05 | 2022-2025 | Wakix |
| Philips North America LLC | $416.75 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.92 | 2022-2025 | Ofev, Jascayd |
| Amgen INC. | $200.30 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $166.91 | 2023-2025 | Aralast |
| Insmed, INC. | $145.18 | 2023-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $141.14 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $127.11 | 2023-2024 | Yupelri |
| United Therapeutics Corporation | $112.06 | 2023-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $72.24 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $49.99 | 2024-2025 | Xolair |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $48.45 | 2023 | Hillrom - Life 2000 Ventilation System |
| Ani Pharmaceuticals, INC. | $46.05 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $44.20 | 2025 | |
| Merck Sharp & Dohme LLC | $39.78 | 2023-2024 | Belsomra, Winrevair |
| Novo Nordisk INC | $36.59 | 2025 | Wegovy |
| Axsome Therapeutics, INC. | $35.42 | 2023 | Sunosi |
| Lilly USA, LLC | $35.21 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $32.63 | 2024 | |
| Soleno Therapeutics, INC. | $21.93 | 2025 | Vykat Xr |
| Inspire Medical Systems, INC. | $19.22 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $18.45 | 2025 | |
| Electromed, INC. | $18.26 | 2025 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $15.75 | 2023 | Airduo Digihaler |
| Alexion Pharmaceuticals, INC. | $15.60 | 2024 | Ultomiris |
| Paratek Pharmaceuticals, INC. | $13.10 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thamar Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.